OVID — Ovid Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1636651 ·
Last close
$2.34
Market Cap
$457.00M
52W High
$3.11
52W Low
$1.18
ADV30
1,662,875
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 733,000 | — | -15,698,000 | -15,009,000 | 231,973,000 | 11,327,000 | 22,083,000 |
| Mar 2026 | 0 | — | -17,846,000 | -16,988,000 | 225,628,000 | 94,064,000 | 27,359,000 |
| Dec 2025 | 718,000 | — | -12,293,000 | 9,663,000 | 150,934,000 | 13,153,000 | 20,274,000 |
| Sep 2025 | 132,000 | — | -12,523,000 | -12,158,000 | 63,848,000 | 20,611,000 | 19,150,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-41,952,000
Investing CF
$-49,006,000
Financing CF
$164,176,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.29
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-338,701,000
Inventory
—
Receivables
—
ST Investments
$61,458,000
EBIT TTM
$-47,735,000
Pretax Income TTM
$-24,167,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,583,000
EBITDA
$-57,974,000
Free Cash Flow
$-33,121,250
Enterprise Value
$420,847,232
Total Cash
$117,219,000
Total Debt
$12,715,000
Shares Out
195,297,857
Trailing EPS
$-0.21
Book Value
$1.14
ROE
-26.0%
ROA
-23.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,252,000 | -42,439,000 | -17,414,000 | 150,934,000 | 20,274,000 | 130,660,000 | -38,334,000 |
| Dec 2024 | 566,000 | -61,885,000 | -26,433,000 | 92,167,000 | 23,941,000 | 68,226,000 | -55,956,000 |
| Dec 2023 | 392,000 | -59,281,000 | -52,339,000 | 144,027,000 | 56,229,000 | 87,798,000 | -45,781,000 |
| Dec 2022 | 1,502,748 | -55,547,651 | -54,169,029 | 155,265,814 | 22,993,250 | 132,272,564 | -55,227,127 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$7,122,000
NetIncome TTM
$-24,167,000
OpCashFlow TTM
—
Assets (Latest)
$225,628,000
Forward EPS
$-0.39
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $2.34 · call volume: 2 · put volume: 55
Expected Move to 2026-10-16:
±$0.35
(14.96%) —
implied range
$1.99 –
$2.69
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SPRY | ARS Pharmaceuticals, Inc. | $453.48M | $4.56 | — |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | $464.63M | $22.82 | — |
| VREOF | Vireo Growth Inc. | $464.97M | $9.15 | — |
| RZLT | Rezolute, Inc. | $448.79M | $4.64 | — |
| KMDA | KAMADA LTD | $448.70M | $7.78 | — |
News headlines (Yahoo Finance, 1h cache)
Ovid Therapeutics (OVID) Stock Gets Fair Value Boost As Analysts Focus On OV329
2026-10-08 09:13 · Yahoo
Ovid Therapeutics to Participate in Upcoming Investor Conferences
2026-09-03 12:00 · Yahoo
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?
2026-08-18 16:00 · Yahoo
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
2026-08-13 12:30 · Yahoo
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
2026-08-05 14:00 · Yahoo
Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer
2026-07-14 10:33 · Yahoo
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
2026-07-08 11:00 · Yahoo
Ovid Therapeutics to Participate in Upcoming Investor Conferences
2026-06-04 11:00 · Yahoo
Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
2026-06-03 11:00 · Yahoo
We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely
2026-05-14 10:51 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.